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Abstract
Background: The role of bacterial pathogens in lactational mastitis remains unclear. The objective
of this study was to compare bacterial species in breast milk of women with mastitis and of healthy
breast milk donors and to evaluate the use of antibiotic therapy, the symptoms of mastitis, number
of health care contacts, occurrence of breast abscess, damaged nipples and recurrent symptoms in
relation to bacterial counts.
Methods: In this descriptive study, breast milk from 192 women with mastitis (referred to as
cases) and 466 breast milk donors (referred to as controls) was examined bacteriologically and
compared using analytical statistics. Statistical analyses were also carried out to test for
relationships between bacteriological content and clinical symptoms as measured on scales,
prescription of antibiotics, the number of care contacts, occurrence of breast abscess and recurring
symptoms.
Results: Five main bacterial species were found in both cases and controls: coagulase negative
staphylococci (CNS), viridans streptococci, Staphylococcus aureus (S. aureus), Group B streptococci
(GBS) and Enterococcus faecalis. More women with mastitis had S. aureus and GBS in their breast
milk than those without symptoms, although 31% of healthy women harboured S. aureus and 10%
had GBS. There were no significant correlations between bacterial counts and the symptoms of
mastitis as measured on scales. There were no differences in bacterial counts between those
prescribed and not prescribed antibiotics or those with and without breast abscess. GBS in breast
milk was associated with increased health care contacts (p = 0.02). Women with ≥ 107 cfu/L CNS
or viridans streptococci in their breast milk had increased odds for damaged nipples (p = 0.003).
Conclusion: Many healthy breastfeeding women have potentially pathogenic bacteria in their
breast milk. Increasing bacterial counts did not affect the clinical manifestation of mastitis; thus
bacterial counts in breast milk may be of limited value in the decision to treat with antibiotics as
results from bacterial culture of breast milk may be difficult to interpret. These results suggest that
the division of mastitis into infective or non-infective forms may not be practically feasible. Daily
follow-up to measure the subsidence of symptoms can help detect those in need of antibiotics.
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Background
Appropriate treatment for inflammatory symptoms of the
breast in lactating women has been under discussion in
the scientific literature for some time. One reason why
consensus has not been reached is that the clinical spec-
trum of "mastitis" covers a range from focal inflammation
with minimal systemic response to septicaemia [1].
According to a review by the World Health Organization
(WHO), the incidence of mastitis varies greatly, from
2.6% to 33%, among breastfeeding women [2]. This sug-
gests that due to difficulties in the definition of the term
"mastitis" [3], researchers might not have been investigat-
ing comparable groups of women. Furthermore, the lack
of internationally agreed scales for the measurement of
symptoms creates difficulties in the use of meta-analyses.
The role of bacterial pathogens in lactational mastitis is
unclear [1-4]. In the 1980s, Thomsen et al suggested that
levels > 106 cfu/L of pathogenic bacteria in breast milk was
an indication for antibiotic treatment since this level,
together with leukocytosis was indicative of infection
[5,6]. Others have suggested that untreated cases may
recover as quickly as treated cases [7] and that bacteriolog-
ical examination of breast milk may be of limited value
[8].
The aims of this study were to compare bacterial species in
breast milk of mothers with mastitis and of healthy breast
milk donors and to evaluate in relation to bacterial
counts, the use of antibiotic therapy, the symptoms of
mastitis as measured on scales, number of health care con-
tacts, occurrence of breast abscess, occurrence of damaged
nipples and recurrence of symptoms.
Methods
Study population
The case group consisted of 205 women who contacted a
breastfeeding clinic in southern Sweden during 2002 –
2004 because of inflammatory symptoms of the breast
during lactation and had agreed to join a randomised con-
trolled trial of care interventions [4]; registration number
of the RCT is: NCT00405158. The incidence of mastitis in
the uptake area was estimated as 6% of the breastfeeding
population [4]. Of the 205 women, 192 (94%) had their
breast milk sampled and sent for bacteriological investiga-
tion. A follow-up questionnaire inquiring about recurrent
symptoms and the women's views on care given was sent
by post to the cases, six-weeks following their last contact
with the breastfeeding clinic. A total of 176 (84%)
returned the questionnaire.
The control group consisted of 466 healthy, prospective
breast milk donors living in the same geographical area as
the case group and studied during the same period of
time. According to Swedish recommendations, women
with an established lactation who wish to donate breast
milk for use in neonatal units are obliged to leave milk for
bacterial analysis before being accepted as donors.
Ethical considerations
Ethical approval for the randomised controlled trial
(RCT) was granted by the Committee for Medical
Research Ethics, Lund University Hospital, Sweden (pro-
tocol number LU 592–00). Two of the authors (CS and
AS) are employed at the laboratory where the specimens
are tested and therefore had access to the material. After
analysis of milk samples and reporting of results to the
neonatal units who submitted the samples, a database,
without any means of identification of individual samples
was set up. Since personal data of the controls were
unknown to the researchers, results of their breast milk
cultures could not be traced to individuals.
Signs and symptoms of breast inflammation
Women were considered to have mastitis when at least
two of the following signs or symptoms were present:
breast erythema, increased breast tension not relieved by
breastfeeding, maternal fever, pain in the breast and
lumps in the breast tissue [4]. A midwife at the breastfeed-
ing clinic carried out the initial measurement of signs and
symptoms together with the woman. Scores for these
signs and symptoms were estimated on scales, which were
tested for internal consistency using Cronbach's alpha [9].
The alpha score on contact day three was 0.79 [4,10].
Scores were added to create a Severity Index (SI), range 0
(least severe) to 19. Table 1 shows the values for the scales.
At subsequent daily telephone follow-ups, the women
were asked to report their scores in relation to their scores
Table 1: The scales used for the measurements of mastitis signs and symptoms in the RCT
Erythema Breast tension
No redness = 0 No change = 0
Slight redness in limited area = 1 Firm, no tenderness = 1
Redness in limited area = 2 Tense, not uncomfortable = 2
Bright red in limited area = 3 Tense and uncomfortable = 3
Bright red over most of the breast = 4 Tense and painful = 4
Very tense and very painful = 5
Pain was measured by Visual Analogue Scale: 0 = no pain, 10 = worst possible pain. Severity Index = Erythema + Breast tension + Pain: range 0–19International Breastfeeding Journal 2008, 3:6 http://www.internationalbreastfeedingjournal.com/content/3/1/6
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on the previous day. The same midwife carried out the tel-
ephone follow-ups as far as possible but this was not
always the case. The number of midwives involved in the
study was seven.
Collection of samples
Both cases and controls were asked to provide a sample of
breast milk for bacterial culture and the samples were all
examined at the same laboratory. The nipple and areola of
the affected breast was cleaned with normal saline solu-
tion; the woman was given non-sterile surgical gloves and
asked to manually express several drops of milk, which
were discarded before collecting the specimen directly
into the test tube. In cases of bilateral symptoms (14%),
milk was sampled from the breast which was most
affected. The controls provided a sample of milk pooled
from both breasts. In the case group, the women were
informed that the results of culture would be available
after two to three days, by which time it was expected that
they would be on the way to recovery. A sample of breast
milk was obtained from each of the 192 cases and all 466
of the control subjects.
Bacteriological analysis of breast milk
Breast milk samples were refrigerated until transport to
the laboratory within 24 hours. Tenfold dilutions of milk
were plated on horse blood agar (HBA) and incubated at
37°C aerobically for two days. Bacterial species were
quantified and identified according to standard methods.
Statistical analysis
The material was analysed using SPSS version 14.0 (SPSS,
Inc., Chicago, USA). Five main bacterial species occurred
in sufficient numbers of specimens to allow statistical
comparisons between cases and controls. Odds Ratios
(OR) with 95% confidence intervals (CI) were calculated
for the occurrence of mastitis for each of these species.
Pearson's correlation test was used to assess possible cor-
relations between bacterial counts and symptoms at first
contact: maternal temperature, breast erythema, increased
breast tension, pain and SI (0–19). Differences in mean
bacterial counts between cases who received or did not
receive antibiotics and between those with and without
abscess were assessed using the independent samples t-
test. In accordance with the level of bacterial content
described by Thomsen et al [5,6] variables for the five
main bacterial species in the mastitis group were dichot-
omised to ≤106 cfu/L milk and ≥107 cfu/L milk. Odds
Ratios with 95% confidence intervals were then calculated
for the proportions of cases with higher or lower levels of
the five bacterial categories vs. prescription of antibiotics,
occurrence of residual symptoms within six weeks and for
the occurrence of damaged nipples. The independent
samples t-test was used to assess whether those with any
one of the five main bacterial species in breast milk
required prolonged contact with the breastfeeding clinic.
Significance was assumed at the 0.05 level.
Results
Comparison of bacterial findings in cases and controls
Microbiological findings are summarized in Table 2. The
five main bacterial species found in cases and controls
were coagulase negative staphylococci (CNS), viridans
streptococci,  Staphylococcus aureus (S. aureus), Group B
streptococci (GBS) and Enterococcus faecalis. CNS were
detected significantly more often in the milk of the
healthy controls than among cases (OR: 0.60, 95%CI:
0.35, 0.91). In contrast, three of the other species were
present significantly more often among cases than con-
trols: viridans streptococci: (OR: 1.43, 95%CI: 1.02, 2.01)
S. aureus: (OR: 1.81, 95%CI: 1.29, 2.60) and GBS: (OR:
2.40, 95%CI: 1.50, 3.71).
Correlations between symptoms and bacterial counts
There were no significant correlations between bacterial
counts of the five main species in the breast milk and
maternal temperature, breast erythema, breast tension,
pain, or the Severity Index at first contact (Table 3).
Bacteria and number of contact days with breastfeeding 
clinic
Occurrence of GBS in the breast milk was associated with
a significant increase in the number of contact days with
the breastfeeding clinic (t = -2.44, p = 0.02). In contrast,
presence of CNS, viridans streptococci or S. aureus did not
affect the number of health care contact days.
Antibiotic therapy, breast abscess, recurrence of symptoms 
and damaged nipples in relation to bacterial counts
Seven of the women (3.3% of the cases) were prescribed
antibiotics on the basis of their symptoms alone, before
results of bacterial cultures were available. A total of 24
(11.4%) cases were prescribed antibiotics on the basis of
culture results, including those who developed a breast
abscess during contact with the breastfeeding clinic. Thus,
a total of 31 (15%) women in the case group received
antibiotic treatment. Table 4 shows the outcome of cul-
ture from the breast milk of women who were prescribed
antibiotics on the basis of symptoms alone and women
who developed a breast abscess during contact with the
breastfeeding clinic. Among the cases there were no signif-
icant differences in bacterial counts of those given (n =
31) vs not given (n = 161) antibiotics or those with (n =
7) vs without a breast abscess (n = 185). Less than half
(42%) of the 31 women who were given antibiotics had S.
aureus in their breast milk. The odds for damaged nipples
was increased when ≥ 107 cfu/L of CNS or viridans strep-
tococci was present in the breast milk: CNS: OR: 2.51
(95%CI: 1.33, 4.61) and viridans streptococci: OR: 2.54
(95%CI: 1.34, 4.90).International Breastfeeding Journal 2008, 3:6 http://www.internationalbreastfeedingjournal.com/content/3/1/6
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At a six-week postal follow-up of the cases, 21 women
(12% of respondents) reported contacting health care
providers because of recurrent symptoms and antibiotics
had been prescribed for eight of them. Out of these eight
women, five had previously received a course of antibiotic
treatment for their initial symptoms. One further woman
reported a breast abscess. There were no reports of
infected infants in the case group. Of the 21 who con-
tacted health services because of recurrent symptoms
within six weeks, ten were positive for S. aureus. There
were no increased odds for recurrence of symptoms when
the bacterial counts were ≥107 cfu/L for any of the five spe-
cies.
Discussion
It was shown, somewhat surprisingly, that many women
with potential pathogens in their breast milk, even at high
bacterial counts, either recovered spontaneously from
mastitis or did not have any symptoms of mastitis (as seen
among control women). Furthermore, it was demon-
strated that increasing bacterial counts did not influence
the clinical manifestation of mastitis. The breast milk of
women who were given antibiotics because of their symp-
toms, did not contain higher bacterial counts than those
who were not given antibiotics. These results and the find-
ing that so many healthy women harboured potential
pathogens in their breast milk may indicate that the divi-
sion of mastitis into infective or non-infective forms may
not be practically feasible. Although only 15% of women
Table 2: Bacterial findings in breast milk of women with and without symptoms of mastitis: Odds Ratios with 95% confidence intervals 
for symptoms of mastitis
Healthy donors (n = 466) Women with mastitis (n = 192)
Bacterial Species Occurrence of bacteria 
in breast milk n (%)
Mean (SD) counts 
(cfu/L)
Occurrence of bacteria in 
breast milk n (%)
Mean (SD) counts 
(cfu/L)
Odds Ratio for 
occurrence of mastitis 
symptoms (95%CI)
CNS 419 (90%) 106(± 1.1) 160 (83%) 106(± 1.1) 0.60 (0.35, 0.91)
p = 0.02
Viridans Streptococci 233 (50%) 105(± 1.0) 113 (59%) 105(± 1.0) 1.43 (1.02, 2.01)
p = 0.04
Staphylococcus aureus 145 (31%) 106(± 1.2) 87 (45%) 106(± 1.3) 1.81 (1.29, 2.60)
p = 0.001
Group B streptococci 47 (10%) 106(± 1.5) 41 (21%) 106(± 1.4) 2.40 (1.50, 3.71)
p = <0.001
Entercoccus faecalis 28 (6%) 106(± 1.1) 16 (8%) 106(± 1.1) 0.70 (0.36, 1.43)
p = 0.36
Group G streptococci 6 (1%) 106 3 (2%) 107
Group A streptococci 3 (1%) 107 2 (1%) 107
Pneumococci 4 (1%) 107 5 (3%) 105
Corynebacteria 2 (0.4%) 104 1 (0.5%) 105
Enterobacteriaceae 36 (8%) 106 2 (1%) 106
Acinetobacter species 12 (3%) 106 00
Pseudomonas species 24 (5%) 107 1 (0.5%) 106
Bacillus species 5 (1%) 105 1 (0.5%) 104
Propionibacterium 
species
3 (1%) 106 2 (1%) 106
Candida species 4 (1%) 105 4 (2%) 105
CNS = coagulase negative staphylococci, SD = Standard Deviation
Table 3: Correlations between symptoms and bacterial counts in women with mastitis (n = 192)
Bacterial species
CNS Viridans streptococci Staphylococcus aureus Group B Streptococci Enterococcus faecalis
Symptoms
Fever r = 0.20
p = 0.06
r = 0.14
p = 0.21
r = 0.05
p = 0.72
r = 0.09
p = 0.63
r = 0.15
p = 0.62
Erythema r = 0.06
p = 0.44
r = 0.008
p = 0.93
r = 0.15
p = 0.16
r = -0.21
p = 0.30
r = 0.24
p = 0.38
Unrelieved breast tension r = -0.04
p = 0.64
r = 0.11
p = 0.30
r = -0.01
p = 0.95
r = -0.05
p = 0.75
r = 0.41
p = 0.11
Pain r = -0.02
p = 0.90
r = 0.74
p = 0.43
r = 0.05
p = 0.62
r = -0.24
p = 0.14
r = 0.42
p = 0.90
Severity Index r = -0.01
p = 0.91
r = 0.07
p = 0.50
r = 0.09
p = 0.45
r = -0.21
p = 0.18
r = 0.31
p = 0.30
r = Pearson's correlation coefficient, CNS = coagulase negative staphylococciInternational Breastfeeding Journal 2008, 3:6 http://www.internationalbreastfeedingjournal.com/content/3/1/6
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with mastitis were given antibiotics, most of them recov-
ered spontaneously with few cases of recurrent symptoms
within 6 weeks requiring antibiotic treatment.
The diagnostic criteria for mastitis used in this study con-
sisted of clinical signs and symptoms, which are in the
main subjective. This implies that the scope of illness
reported in the case group may have been quite broad,
ranging from mild to very severe. However, the 6% inci-
dence of mastitis in the breastfeeding population was low
compared to the range reported by WHO (2.6% – 33%),
which suggests that the women in the RCT were correctly
diagnosed. The incidence of 3.3% of breast abscess devel-
opment in the group with mastitis can be compared to
data from a recent study from Australia, which showed
that 14.5% of breastfeeding women were treated with
antibiotics and 2.9% of the women with mastitis devel-
oped an abscess [11]. Leukocyte counts have previously
been used as a marker of infective mastitis [5]. However,
it was not possible in the present study to measure leuko-
cyte levels since the cases were originally included in a
RCT of care interventions where measurement of infec-
tion was not the primary aim. Bacterial content in breast
milk may vary over time and by geographical location and
therefore the findings of this study may not be applicable
to all communities.
Our analysis suggested that the two most abundant bacte-
rial species or groups found, CNS and viridans strepto-
cocci, were not linked to clinical mastitis; these are well
established as major components of the resident skin or
throat flora and possibly of importance for protection
against pathogens [12]. Interestingly, Heikkilä and Saris
found that human breast milk contains commensal bacte-
ria that inhibit S. aureus and may prevent maternal breast
infections [13]. Two potentially pathogenic species, S.
aureus and GBS, were recovered more frequently in masti-
tis cases as compared to controls, indicating an active role
in mastitis. In particular, S. aureus has earlier been
reported as a primary causative organism in mastitis [14-
16] and might conceivably be expected to give rise to
breast abscess. The breast milk samples of five of the seven
women with a breast abscess was positive for S. aureus, but
these figures are too small to allow any conclusions to be
drawn. The inflammation in mastitis occurs in the con-
nective tissue of the breast and for this reason causative
organisms may be difficult to isolate from breast milk.
It was stated in a WHO review on mastitis that antibiotic
treatment is indicated if either cell or bacterial colony
counts are available and indicate infection or symptoms
are severe from the beginning or a nipple fissure is visible
or symptoms do not improve after 12–24 hours of
improved milk removal [2]. If these criteria had been fol-
lowed, many more than the 15% of cases, as reported
here, would have received antibiotics. Reports from indus-
trialised countries such as Australia [17-19] and USA
[20,21] have shown that 77% – 97% of women with lac-
Table 4: Bacterial findings in breast milk of i) women prescribed antibiotics on the basis of symptoms alone and ii) women who 
presented with or developed abscess during treatment
Concentrations of bacterial species expressed in cfu/L
CNS S. aureus Viridans streptococci Pneumococci Group B streptococci Group A streptococi
Women prescribed 
antibiotics on the basis of 
their symptoms
No.1 106 108
No.2 108 105
No.3 106 105
No.4 104 105
No.5 108 108
No.6 Not quantified Not quantified
No.7 No culture carried 
out
Women who presented 
with or developed breast 
abscess during treatment
No.1 107
No.2 106 107 107
No.3 107 107
No.4 106 104
No.5 106 107 105
No.6 106 106
No.7 106 106International Breastfeeding Journal 2008, 3:6 http://www.internationalbreastfeedingjournal.com/content/3/1/6
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tational mastitis are prescribed antibiotics. The findings of
our study do not appear to support this extensive use of
antibiotic treatment for mastitis during lactation. It is
important for all communities to avoid imprudent use of
antibiotics because of the spread of methicillin resistant S.
aureus (MRSA) and other multi-resistant pathogens. It has
also been considered that maternal antibiotic therapy
might disturb the commensal flora of the upper airways in
breastfed infants [22].
The major rationale for treatment of mastitis by antibiot-
ics is to avoid the development of breast abscess. How-
ever, empirical evidence for a continuum from mastitis to
abscess is not readily available and the WHO review sug-
gests that breast abscess may occur seemingly spontane-
ously, irrespective of previous mastitis [2]. Nonetheless,
lactational mastitis has the potential for serious sequelae
such as breast abscess and in rare cases septicaemia [1]
and if clinical signs and symptoms and bacterial culture of
breast milk are unhelpful, we need to consider how to aid
in the decision to prescribe antibiotics. In order to select
which women will not recover without antibiotic treat-
ment, it is necessary to maintain daily contacts with the
women to assure that symptoms are subsiding. Although,
as reported earlier [4] the mean number of contact days
with a breastfeeding clinic was 5 (± 2.9), it is important,
in our opinion, that symptoms improve within 24 to 48
hours after initiation of care interventions. Scales to meas-
ure symptoms may assist clinicians in judging whether
improvement has occurred. Continuity of care provider
will also ensure that women are adequately treated. Those
not improving will need a new consultation with a view
to antibiotic treatment. At this time, results of bacterial
culture may be of value for choice of antibiotic.
The frequent occurrence of GBS in both cases and healthy
mothers was notable. GBS is a leading cause of serious
infection in neonates [23] but no such infections were
reported in the context of this study. Whether certain com-
ponents of breast milk may protect infants and mothers
from invasive GBS infection will be an important area for
future research. Another avenue for investigation might be
to consider why many women who harbour S. aureus do
not develop mastitis. Knowledge of how often breast
abscess occurs during lactation without any noticeable
episode of preceding breast inflammation might also give
us more understanding of the process. Well-designed
RCTs of antibiotic therapy for treatment of lactational
mastitis would help define the optimal level of such treat-
ment for this group. New research could also include
measurement of leukocyte levels.
Conclusion
Potentially pathogenic bacteria, often at high levels, were
found in breast milk from both healthy donors and
women with lactational mastitis. Increasing bacterial
counts did not affect the clinical manifestation of mastitis,
thus bacterial counts in breast milk may be of limited
value in the decision to treat with antibiotics and results
from bacterial culture of breast milk may be difficult to
interpret. These results suggest that division of mastitis
into infective and non-infective forms may not be practi-
cally feasible. Daily follow-up to measure the subsidence
of symptoms can help identify those in need of antibiotic
treatment.
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